Lilly looks to boost pipeline with drug partnerships
A slimmed-down Eli Lilly and Co., thousands of employees lighter after its biggest restructuring in nearly a decade, is now looking high and low for deals to bulk up its drug pipeline.
Eli Lilly and Co.
Articles
Trump health pick wary of government drug price negotiations
Alex Azar, a former Eli Lilly and Co. executive, acknowledged to the Senate Finance Committee that drug prices are too high and said he'd work to lower them if confirmed as secretary of Health and Human Services.
Lilly CEO says tax reform could lead to more dealmaking
Eli Lilly and Co. CEO Dave Ricks said Monday that the recent changes in U.S. tax policy will help the drugmaker lower its global tax burden as he continues to look for deals in areas like oncology.
Hot-selling Lilly drug gets OK for second use
Taltz, launched in 2016 to treat plaque psoriasis, won approval from the Food and Drug Administration for a second indication—treating adults with a form of arthritis.
Lawsuit accuses Lilly of using kickbacks to boost insulin sales
A recently unsealed suit accuses the Indianapolis-based drugmaker of offering free nursing services to doctors to induce them to prescribe the company’s products.
Trump’s HHS nominee reaped big earnings from drug industry tenure
As a top pharma industry veteran from 2007 to 2017, former Eli Lilly and Co. executive Alex Azar built a substantial financial portfolio now worth as much as $20.6 million.
Trump names former Lilly exec as new health secretary
If confirmed by the Senate, former Eli Lilly and Co. exec Alex Azar will oversee a $1 trillion department responsible for major health insurance programs, medical research, food and drug safety, and public health.
Trump expected to name ex-Lilly exec to lead Health & Human Services
Alex Azar, who ran U.S. operations for Eli Lilly before leaving in January, would be the administration’s point person on running—or dismantling—Obamacare.
Assessing Elanco options: sale, spinoff or status quo?
Lilly CEO David Ricks says the time is right “to consider a variety of options to maximize future value,” such as an initial public offering. But analysts say an IPO would make more sense if Elanco were performing better.
Lilly shares slide on news of possible sale, spinoff of Elanco
Despite slipping sales and lost market share, the Elanco animal-health unit is strong and the time is right to explore selling or spinning it off, Eli Lilly and Co. officials said Tuesday.
Lilly considers sale, spinoff of Elanco animal-health business
The company announced Tuesday that it is reviewing options for the Greenfield-based division, "including an initial public offering, merger, sale, or retention of the business."
Lilly plans $72M upgrade for Indianapolis insulin operation
The Indianapolis drugmaker said it will use the money to replace an existing line that fills vials for Humalog and Humulin and to prepare for new insulin products.
Trump considers former Lilly exec for HHS post
Before joining Eli Lilly and Co., Alex Azar served as the general counsel and deputy secretary of Health and Human Services Administration under President George Bush.
Lilly names new CFO, head of R&D
The appointments mark the latest changes in the Indianapolis-based drugmaker’s executive suite since David Ricks took over as CEO in January.
FDA approves Lilly drug for common advanced breast cancer
U.S. regulators have approved a new medicine for treating a common type of breast cancer after it has spread to other parts of the body.
Animal-health biz Elanco under the weather; Lilly won’t rule out spinoff
The Greenfield-based unit, which makes a vast array of vaccines, antibiotics, feed additives and other health products for livestock and pets, is in a slump, after more than a decade of growth.
Lilly breast cancer drug results could challenge Pfizer pill
li Lilly and Co.’s experimental breast cancer drug abemaciclib, when combined with standard therapy, slowed the progression of tumors in patients with an advanced form of the disease.
Lilly eliminating 3,500 jobs as part of cost-cutting plan
Indianapolis-based pharmaceutical giant Eli Lilly and Co. said the 3,500 jobs represent 8.3 percent of its global workforce. Lilly hopes the cuts will save it $500 million a year.
Lilly competitor reaches $46.5M settlement with U.S. over safety info
Danish drugmaker Novo Nordisk says it has reached a settlement over allegations that it hadn’t properly communicated safety information when marketing a medicine to treat type 2 diabetes.
Lilly shares rise on surprising news from FDA on arthritis drug
The Indianapolis drugmaker said it will not be required to conduct another expensive, time-consuming clinical trial for the potential blockbuster.